- Home
- PAYS vs CRDF Comparison
PAYS vs CRDF Comparison
Compare PAYS & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- CRDF
- Stock Information
- Founded
- PAYS 2001
- CRDF 1999
- Country
- PAYS United States
- CRDF United States
- Employees
- PAYS N/A
- CRDF N/A
- Industry
- PAYS Business Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAYS Consumer Discretionary
- CRDF Health Care
- Exchange
- PAYS Nasdaq
- CRDF Nasdaq
- Market Cap
- PAYS 125.2M
- CRDF 144.4M
- IPO Year
- PAYS 1998
- CRDF N/A
- Fundamental
- Price
- PAYS $5.90
- CRDF $2.15
- Analyst Decision
- PAYS Strong Buy
- CRDF Strong Buy
- Analyst Count
- PAYS 4
- CRDF 5
- Target Price
- PAYS $7.31
- CRDF $11.10
- AVG Volume (30 Days)
- PAYS 704.8K
- CRDF 1.0M
- Earning Date
- PAYS 11-04-2025
- CRDF 11-06-2025
- Dividend Yield
- PAYS N/A
- CRDF N/A
- EPS Growth
- PAYS N/A
- CRDF N/A
- EPS
- PAYS 0.12
- CRDF N/A
- Revenue
- PAYS $68,539,381.00
- CRDF $545,000.00
- Revenue This Year
- PAYS $35.12
- CRDF N/A
- Revenue Next Year
- PAYS $20.99
- CRDF N/A
- P/E Ratio
- PAYS $47.68
- CRDF N/A
- Revenue Growth
- PAYS 27.84
- CRDF N/A
- 52 Week Low
- PAYS $1.80
- CRDF $1.90
- 52 Week High
- PAYS $8.88
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- PAYS 55.92
- CRDF 44.15
- Support Level
- PAYS $5.08
- CRDF $1.97
- Resistance Level
- PAYS $5.56
- CRDF $2.27
- Average True Range (ATR)
- PAYS 0.21
- CRDF 0.12
- MACD
- PAYS -0.21
- CRDF 0.04
- Stochastic Oscillator
- PAYS 98.33
- CRDF 67.78
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.